Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies

Trial Profile

Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Decitabine (Primary) ; Sonidegib (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Essential thrombocythaemia; Myelodysplastic syndromes; Myelofibrosis; Polycythaemia vera
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Feb 2018 Planned End Date changed from 1 Apr 2018 to 1 Oct 2018.
    • 05 Feb 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Oct 2018.
    • 12 Dec 2017 First analysis of the final study results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top